Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 16, 2021 - Issue
Submit an article Journal homepage
80
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Increased Serum Soluble Interleukin-2 Receptor Associated with Severity of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Yue ZhangDepartment of Respiratory Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-8611-6124View further author information
ORCID Icon,
Lianping RenDepartment of Respiratory Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, People’s Republic of ChinaView further author information
,
Jinyuan SunDepartment of Respiratory Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, People’s Republic of ChinaView further author information
,
Fengfeng HanDepartment of Respiratory Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, People’s Republic of ChinaView further author information
&
Xuejun GuoDepartment of Respiratory Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 2561-2573 | Published online: 07 Sep 2021

Figures & data

Figure 1 Flow diagram of patients with AECOPD.

Figure 1 Flow diagram of patients with AECOPD.

Table 1 Baseline Clinical and Laboratory Characteristics of Study Population

Table 2 Clinical and Laboratory Characteristics According to the Tertile of sIL-2R

Table 3 Association Between sIL-2R and Adverse Outcomes in Overall Patients with AECOPD and Subgroups Stratified by Related Factors

Table 4 Relationship Between Clinical Parameters and the Serum Concentration of sIL-2R in Each Group

Figure 2 Relationship between clinical parameters and serum concentration of sIL-2R in good and adverse outcomes of AECOPD.

Notes: (A) In the mMRC score of 0–1, 2 and 3–4 groups, sIL-2R concentration was higher in patients with adverse outcomes than in those with good outcomes (P<0.05, P<0.05, P<0.001, respectively); Serum sIL-2R concentration was higher in patients with mMRC 3–4 than in those with mMRC 0–1 in adverse outcomes group (P<0.05); (B) In both GOLD 1–2 and GOLD 3–4 groups, sIL-2R concentration was higher in patients with adverse outcomes than in those with good outcomes (P<0.001, P<0.001, respectively); Serum sIL-2R concentration was higher in patients of adverse outcomes group than in those of good outcomes group in GOLD 1–2 (P<0.05); (C) In both the frequent and non-frequent exacerbation groups, the concentration of sIL-2R was higher in patients with adverse outcomes than in those with good outcomes (P<0.05, P<0.001, respectively); (D) In both the current and former smoker groups, the concentration of serum sIL-2R was higher in patients with adverse outcomes than in those with good outcomes (P<0.05, P<0.001, respectively).
Abbreviations: sIL-2R, soluble interleukin-2 receptor; mMRC score, modified Medical Research Council dyspnoea score; GOLD, Global Initiative for Chronic Obstructive Lung Disease; AECOPD, acute exacerbation of chronic obstructive pulmonary disease.
Figure 2 Relationship between clinical parameters and serum concentration of sIL-2R in good and adverse outcomes of AECOPD.

Figure 3 Relationship between FEV1%pred, FEV1/FVC and serum concentration of sIL-2R in good and adverse outcomes of AECOPD.

Notes: (A) In both high and low FEV1%pred groups, the concentration of serum sIL-2R was higher in patients with adverse outcomes than in those with good outcomes (P<0.001,P<0.001, respectively); (B) In both high and low FEV1/FVC groups, the concentration of serum sIL-2R was higher in patients with adverse outcomes than in those with good outcomes (P<0.05, P<0.001, respectively); Serum sIL-2R concentration was higher in patients with low FEV1/FVC group than in those with high FEV1/FVC group of adverse outcomes (P<0.05).
Abbreviations: sIL-2R, soluble interleukin-2 receptor; FEV1, forced expiratory volume in 1 second; FEV1/FVC, forced expiratory volume in 1 second/force Vital Capacity.
Figure 3 Relationship between FEV1%pred, FEV1/FVC and serum concentration of sIL-2R in good and adverse outcomes of AECOPD.

Table 5 Correlation Between sIL-2R and Other Laboratory Variables in Patients with AECOPD

Figure 4 Diagnostic value of sIL-2R for adverse outcomes of AECOPD (AUC=0.6887).

Figure 4 Diagnostic value of sIL-2R for adverse outcomes of AECOPD (AUC=0.6887).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.